Literature DB >> 27041383

Signal transducer and activator of transcription 5 is implicated in disease activity in adult and juvenile onset systemic lupus erythematosus.

Safa Meshaal1, Rasha El Refai2, Ahmed El Saie3, Rabab El Hawary4.   

Abstract

The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway is one of a handful of pleiotropic cascades used to transduce a multitude of signals for development and homeostasis in humans. It is the principal signaling mechanism for a wide array of cytokines and growth factors. Dysregulated cytokine action on immune cells plays an important role in the initiation and progress of systemic lupus erythematosus (SLE). In this study, we tried to assess the role of STAT5 in systemic lupus erythematosus and correlate its phosphorylation level with the disease activity. The activation of the STAT5 was assessed by measuring the level of expression of phosphorylated STAT5 (pSTAT5) using flow cytometry on the peripheral blood T and B cells in 58 SLE patients (40 adult and 18 juvenile onset) and on 23 healthy age- and sex-matched controls for both groups. Serum prolactin level was also assessed in the patients and control by ELISA. The study revealed that the level of pSTAT5 was higher in adult SLE patients than in healthy control (p = 0.001) and in juvenile-onset SLE patients versus age-matched control (p = 0.031). A positive correlation existed between the pSTAT5 levels and Systemic Lupus Activity Measure (SLAM) score and also with multiple clinical manifestations indicating a potential role of STAT5 signaling in pathogenesis SLE. The pSTAT5 signaling is implicated in the disease activity of SLE and may be a useful target of therapy by correcting the dysregulation of cytokines involved in the disease pathogenesis.

Entities:  

Keywords:  Phosphorylated STAT5; Prolactin; Signaling pathway; Systemic lupus erythematosus

Mesh:

Substances:

Year:  2016        PMID: 27041383     DOI: 10.1007/s10067-016-3250-9

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  31 in total

1.  Elevated bioactive prolactin levels in systemic lupus erythematosus--association with disease activity.

Authors:  M Pacilio; S Migliaresi; R Meli; L Ambrosone; B Bigliardo; R Di Carlo
Journal:  J Rheumatol       Date:  2001-10       Impact factor: 4.666

Review 2.  Signal transduction in CD4+CD25+ regulatory T cells: CD25 and IL-2.

Authors:  Angela M Thornton
Journal:  Front Biosci       Date:  2006-01-01

3.  IL-33 neutralization suppresses lupus disease in lupus-prone mice.

Authors:  Pin Li; Wei Lin; Xiangxiong Zheng
Journal:  Inflammation       Date:  2014-06       Impact factor: 4.092

4.  Disease activity, severity, and damage in the UK Juvenile-Onset Systemic Lupus Erythematosus Cohort.

Authors:  Louise Watson; Valentina Leone; Clarissa Pilkington; Kjell Tullus; Satyapal Rangaraj; Janet E McDonagh; Janet Gardner-Medwin; Nick Wilkinson; Phil Riley; Jane Tizard; Kate Armon; Manish D Sinha; Yiannis Ioannou; Neil Archer; Kathryn Bailey; Joyce Davidson; Eileen M Baildam; Gavin Cleary; Liza J McCann; Michael W Beresford
Journal:  Arthritis Rheum       Date:  2012-07

5.  Targeting transcription factor Stat5a/b as a therapeutic strategy for prostate cancer.

Authors:  Zhiyong Liao; Marja T Nevalainen
Journal:  Am J Transl Res       Date:  2010-11-21       Impact factor: 4.060

6.  Association of increased serum IL-33 levels with clinical and laboratory characteristics of systemic lupus erythematosus in Chinese population.

Authors:  Zaixing Yang; Yan Liang; Weiqiang Xi; Chang Li; Renqian Zhong
Journal:  Clin Exp Med       Date:  2010-10-21       Impact factor: 3.984

7.  Oncostatin M-induced and constitutive activation of the JAK2/STAT5/CIS pathway suppresses CCL1, but not CCL7 and CCL8, chemokine expression.

Authors:  Christoph Hintzen; Claude Haan; Jan P Tuckermann; Peter C Heinrich; Heike M Hermanns
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

Review 8.  Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B.

Authors:  Lothar Hennighausen; Gertraud W Robinson
Journal:  Genes Dev       Date:  2008-03-15       Impact factor: 11.361

Review 9.  STAT5-mediated self-renewal of normal hematopoietic and leukemic stem cells.

Authors:  Hein Schepers; Albertus T J Wierenga; Edo Vellenga; Jan Jacob Schuringa
Journal:  JAKSTAT       Date:  2012-01-01

10.  Overexpression of microRNA-155 increases IL-21 mediated STAT3 signaling and IL-21 production in systemic lupus erythematosus.

Authors:  Tue Kruse Rasmussen; Thomas Andersen; Rasmus Otkjær Bak; Gloria Yiu; Christian Møller Sørensen; Kristian Stengaard-Pedersen; Jacob Giehm Mikkelsen; Paul Joseph Utz; Christian Kanstrup Holm; Bent Deleuran
Journal:  Arthritis Res Ther       Date:  2015-06-09       Impact factor: 5.156

View more
  3 in total

1.  Confirmation of five novel susceptibility loci for systemic lupus erythematosus (SLE) and integrated network analysis of 82 SLE susceptibility loci.

Authors:  Julio E Molineros; Wanling Yang; Xu-Jie Zhou; Celi Sun; Yukinori Okada; Huoru Zhang; Kek Heng Chua; Yu-Lung Lau; Yuta Kochi; Akari Suzuki; Kazuhiko Yamamoto; Jianyang Ma; So-Young Bang; Hye-Soon Lee; Kwangwoo Kim; Sang-Cheol Bae; Hong Zhang; Nan Shen; Loren L Looger; Swapan K Nath
Journal:  Hum Mol Genet       Date:  2017-03-15       Impact factor: 6.150

2.  Identification of enhanced IFN-γ signaling in polyarticular juvenile idiopathic arthritis with mass cytometry.

Authors:  Allison A Throm; Halima Moncrieffe; Amir B Orandi; Jeanette T Pingel; Theresa L Geurs; Hannah L Miller; Allyssa L Daugherty; Olga N Malkova; Daniel J Lovell; Susan D Thompson; Alexei A Grom; Megan A Cooper; Stephen T Oh; Anthony R French
Journal:  JCI Insight       Date:  2018-08-09

Review 3.  STAT3 and STAT5 Targeting for Simultaneous Management of Melanoma and Autoimmune Diseases.

Authors:  Stella Logotheti; Brigitte M Pützer
Journal:  Cancers (Basel)       Date:  2019-09-27       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.